Day: December 1, 2025

If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 seconds Would potentially provide a cost-effective and convenient option to address episodes of fluid buildup at home, benefiting patients, providers and payors PDUFA target action date of July 26, 2026WESTLAKE VILLAGE, Calif. and BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD) today announced that the U.S. Food and Drug Administration (FDA) has accepted the sNDA seeking approval for FUROSCIX ReadyFlow™ Autoinjector (SCP-111), developed to deliver a subcutaneous furosemide injection in under 10 seconds as an investigational alternative to the FDA-approved FUROSCIX® (furosemide) On-body Infusor for treatment of edema in adult patients with chronic...

HANOVER, Germany, Dec. 01, 2025 (GLOBE NEWSWIRE) — CHC Navigation (CHCNAV), a global leader in precision agriculture technologies, has announced a strategic partnership with CNH Industrial (CNH) at Agritechnica 2025 in Hanover. This collaboration brings CHCNAV’s high-precision guidance systems into CNH’s new FP FleetPro aftermarket kits, providing accessible and reliable precision agriculture tools to a wider farming audience. Making Precision Farming More Accessible The partnership centers around the integration of CHCNAV’s technology into CNH’s FP FleetPro aftermarket product line. These guidance kits are designed to deliver cost-effective, easy-to-use solutions that can be installed across various equipment types. Key features of the FP FleetPro guidance kits include:10-inch and 12-inch user-friendly displays Universal compatibility...

WILMINGTON, Del., Dec. 01, 2025 (GLOBE NEWSWIRE) — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, the “Company”, “NRx”), a clinical-stage biopharmaceutical company and HOPE Therapeutics, an interventional psychiatry network owned by NRx, today announced that its Founder, Chairman, and Chief Executive Officer, Jonathan Javitt, M.D., M.P.H will present at NobleCon21 – Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL.- on Wednesday, December 3rd at 4:30 PM EST. The presentation will provide an update on the Company’s expanded focus following progress achieved over the past year across investigational drugs, medical devices, and interventional psychiatric therapies for suicidal depression, PTSD, and related conditions. As previously...

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025 at 8:20am ET. Webcast details will be accessible from the “Investors & Media” section of ProQR’s website (www.proqr.com) under “Events“. Archived webcasts will be available for approximately 30 days following the presentation date. About Axiomer™ ProQR is pioneering a next-generation RNA base editing technology called Axiomer™, which could potentially yield a new class...

Jerry Durso, accomplished industry leader, to succeed Vipin Garg, Ph.D. as Chief Executive Officer Transition follows seven years of strong leadership by Dr. Garg GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and metabolic diseases, today announced a CEO succession plan under which Vipin Garg, Ph.D. will step down as the Company’s President and Chief Executive Officer effective January 1, 2026. Altimmune’s Chairman of the Board, Jerry Durso, will assume the role of President and Chief Executive Officer and retain his position as Chairman. To facilitate a smooth transition, Dr. Garg will serve as an advisor to the Company through June 30, 2026. Since 2018, Dr. Garg has guided Altimmune into becoming...

New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in patients with Dravet syndrome treated with zorevunersen support the potential for disease modification CAMBRIDGE, Mass and BEDFORD, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced data presentations from studies of zorevunersen at the 2025 American Epilepsy Society (AES) Annual Meeting, taking place December 5-9 in Atlanta, Georgia. Zorevunersen is an investigational antisense oligonucleotide currently being evaluated as a potential first-in-class medicine for the treatment of Dravet syndrome, a severe developmental...

Rick Seadler, Bowling Green Market PresidentStock Yards Bank & TrustLOUISVILLE, Ky., Dec. 01, 2025 (GLOBE NEWSWIRE) — Rick Seadler has joined Stock Yards Bank & Trust as its Bowling Green Market President. Prior to joining the bank, Seadler served as the Regional President at Pinnacle Financial Partners in Bowling Green. With more than 35 years of banking experience, he has also held leadership roles in Louisville, Ky. and Nashville, Tenn. at Commerce Bank and National City Bank (PNC). Stock Yards Bank & Trust Chairman and Chief Executive Officer Ja Hillebrand said, “We’re thrilled to welcome Rick to our team. His long tenure in banking showcases his ability to lead and grow business by forming lasting client relationships and getting involved in the heart of the community.” Phil Poindexter, President, Stock...

Vancouver, British Columbia, Dec. 01, 2025 (GLOBE NEWSWIRE) — North America Niobium and Critical Minerals Corp. (CSE: NIOB) (FSE: IOR) (OTCQB: NIOMF) (“North American Niobium” or the “Company”) is pleased to announce its fully-funded comprehensive 2026 exploration program across its district-scale land package of 29,936-hectare niobium and rare earth elements focused land position in Quebec’s prolific Grenville Province. The work program is designed to confirm, expand, and advance multiple niobium and rare earth elements targets hosted within carbonatite, syenite, and niobium, yttrium, and fluorine-type (NYF) pegmatite systems – geological environments known to host major critical element deposits. Within its broader portfolio, four properties will be the focus for 2026, each hosting mineral occurrences of rare earth elements...